Julie Teruya-Feldstein

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint MUC-1 mucin protein expression in B-cell lymphomas
    Julie Teruya-Feldstein
    Department of Pathology, Cell Biology and Immunology Programs, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Appl Immunohistochem Mol Morphol 11:28-32. 2003
  2. ncbi request reprint The role of chemokines in Hodgkin's disease
    J Teruya-Feldstein
    Department of Pathology, Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Leuk Lymphoma 38:363-71. 2000
  3. ncbi request reprint Getting the diagnosis right in NHL: role of immunohistochemistry and molecular diagnostic testing
    Julie Teruya-Feldstein
    Immunohistochemistry Laboratory, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Natl Compr Canc Netw 6:422-7. 2008
  4. ncbi request reprint CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients
    J Teruya-Feldstein
    Department of Pathology, Memorial Sloan Kettering Cancer Center, NY 10021, USA
    Ann Oncol 15:1673-9. 2004
  5. doi request reprint The immunohistochemistry laboratory: looking at molecules and preparing for tomorrow
    Julie Teruya-Feldstein
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Arch Pathol Lab Med 134:1659-65. 2010
  6. ncbi request reprint CD5 negative, Cyclin D1-positive diffuse large B-cell lymphoma (DLBCL) presenting as ruptured spleen
    Julie Teruya-Feldstein
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Appl Immunohistochem Mol Morphol 17:255-8. 2009
  7. ncbi request reprint Diffuse large B-cell lymphomas with plasmablastic differentiation
    Julie Teruya-Feldstein
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Curr Oncol Rep 7:357-63. 2005
  8. ncbi request reprint Analysis of mismatch repair defects in the familial occurrence of lymphoma and colorectal cancer
    J Teruya-Feldstein
    Department of Pathology, Memorial Sloan Kettering Cancer Center, Memorial Hospital, New York, NY 10021, USA
    Leuk Lymphoma 43:1619-26. 2002
  9. ncbi request reprint PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR
    Rosa Bernardi
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, 1275 York Avenue, New York, New York 10021, USA
    Nature 442:779-85. 2006
  10. ncbi request reprint Role of the proto-oncogene Pokemon in cellular transformation and ARF repression
    Takahiro Maeda
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, 1275 York Avenue, New York, New York 10021, USA
    Nature 433:278-85. 2005

Collaborators

Detail Information

Publications85

  1. ncbi request reprint MUC-1 mucin protein expression in B-cell lymphomas
    Julie Teruya-Feldstein
    Department of Pathology, Cell Biology and Immunology Programs, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Appl Immunohistochem Mol Morphol 11:28-32. 2003
    ..For all cases, MUC-1 mucin expression correlated with a previous history of lymphoma (p=0.003)...
  2. ncbi request reprint The role of chemokines in Hodgkin's disease
    J Teruya-Feldstein
    Department of Pathology, Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Leuk Lymphoma 38:363-71. 2000
    ..In addition, we discuss the potential role of chemokines and cytokines in the pathobiology of HD...
  3. ncbi request reprint Getting the diagnosis right in NHL: role of immunohistochemistry and molecular diagnostic testing
    Julie Teruya-Feldstein
    Immunohistochemistry Laboratory, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Natl Compr Canc Netw 6:422-7. 2008
    ....
  4. ncbi request reprint CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients
    J Teruya-Feldstein
    Department of Pathology, Memorial Sloan Kettering Cancer Center, NY 10021, USA
    Ann Oncol 15:1673-9. 2004
    ....
  5. doi request reprint The immunohistochemistry laboratory: looking at molecules and preparing for tomorrow
    Julie Teruya-Feldstein
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Arch Pathol Lab Med 134:1659-65. 2010
    ....
  6. ncbi request reprint CD5 negative, Cyclin D1-positive diffuse large B-cell lymphoma (DLBCL) presenting as ruptured spleen
    Julie Teruya-Feldstein
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Appl Immunohistochem Mol Morphol 17:255-8. 2009
    ..The patient received multiple therapies and ultimately died. This case raises the differential diagnoses of pleomorphic mantle cell lymphoma and other aggressive lymphomas with pleomorphic, anaplastic, and Reed-Sternberg-like cells...
  7. ncbi request reprint Diffuse large B-cell lymphomas with plasmablastic differentiation
    Julie Teruya-Feldstein
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Curr Oncol Rep 7:357-63. 2005
    ..In this review, we discuss recently described clinicopathologic insights, case observations, and recently reported molecules involved in terminal B-cell or plasma cell differentiation and their possible roles in disease pathogenesis...
  8. ncbi request reprint Analysis of mismatch repair defects in the familial occurrence of lymphoma and colorectal cancer
    J Teruya-Feldstein
    Department of Pathology, Memorial Sloan Kettering Cancer Center, Memorial Hospital, New York, NY 10021, USA
    Leuk Lymphoma 43:1619-26. 2002
    ....
  9. ncbi request reprint PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR
    Rosa Bernardi
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, 1275 York Avenue, New York, New York 10021, USA
    Nature 442:779-85. 2006
    ..Thus, our findings identify PML as a novel suppressor of mTOR and neoangiogenesis...
  10. ncbi request reprint Role of the proto-oncogene Pokemon in cellular transformation and ARF repression
    Takahiro Maeda
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, 1275 York Avenue, New York, New York 10021, USA
    Nature 433:278-85. 2005
    ..Pokemon's critical role in cellular transformation makes it an attractive target for therapeutic intervention...
  11. ncbi request reprint p63 expression profiles in human normal and tumor tissues
    Charles J Di Como
    Division of Molecular Pathology, Department of Pathology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 8:494-501. 2002
    ..The p63 gene, located on chromosome 3q27-28, is a member of the p53 gene family. The product encoded by the p63 gene has been reported to be essential for normal development...
  12. ncbi request reprint High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging
    Craig H Moskowitz
    Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Br J Haematol 148:890-7. 2010
    ..61. Risk-adapted augmentation of salvage treatment in patients with HL is feasible and improves EFS in poorer-risk patients. Our data suggest that normalisation of FI pre-ASCT predicts outcome, and should be the goal of salvage treatment...
  13. ncbi request reprint Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL
    Craig H Moskowitz
    Lymphoma and Hematology Services of the Division of Hematological Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 106:3383-5. 2005
    ..The cell of origin as determined by IHC does not predict outcome in transplantation-eligible patients with relapsed or primary refractory DLBCL...
  14. ncbi request reprint A CK2-dependent mechanism for degradation of the PML tumor suppressor
    Pier Paolo Scaglioni
    Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cell 126:269-83. 2006
    ..These data identify a key posttranslational mechanism that controls PML protein levels and provide therapeutic means toward PML restoration through CK2 inhibition...
  15. pmc Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence
    Hui Kuan Lin
    Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Nature 464:374-9. 2010
    ..Our findings therefore provide proof-of-principle evidence that pharmacological inhibition of Skp2 may represent a general approach for cancer prevention and therapy...
  16. ncbi request reprint Expression of p63 in diffuse large B-cell lymphoma
    Cyrus V Hedvat
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Appl Immunohistochem Mol Morphol 13:237-42. 2005
    ..Even though in univariate analysis p63 expression did not correlate with overall survival, the association of p63 with increased proliferative index suggests its involvement in DLBCL tumor progression...
  17. pmc Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma
    Craig H Moskowitz
    Departments of Medicine, Radiology, Pathology, and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 28:1896-903. 2010
    ..Outside of a clinical trial, we recommend biopsy confirmation of an abnormal interim FDG-PET scan before changing therapy...
  18. ncbi request reprint Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma
    Tarun Kewalramani
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 103:3684-8. 2004
    ..25). RICE appears to induce very high CR rates in patients with relapsed and refractory DLBCL; however, further studies are necessary to determine whether this treatment regimen will improve outcomes after ASCT...
  19. ncbi request reprint Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas
    Jane Houldsworth
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 103:1862-8. 2004
    ..Nonetheless, these data indicate that DLBCLs are heterogeneous with respect to REL and thus nuclear factor-kappaB (NF-kappaB) activity...
  20. doi request reprint High dose chemoradiotherapy and ASCT may overcome the prognostic importance of biologic markers in relapsed/refractory Hodgkin lymphoma
    Daniel O Persky
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Appl Immunohistochem Mol Morphol 18:35-40. 2010
    ..We sought to determine if we could identify such markers, and if our comprehensive second-line program could overcome their significance...
  21. pmc Dissecting eIF4E action in tumorigenesis
    Hans Guido Wendel
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Genes Dev 21:3232-7. 2007
    ..Our results provide insight into how eIF4E contributes to tumorigenesis and pinpoint a level of translational control that may be suitable for therapeutic intervention...
  22. ncbi request reprint Molecular cytogenetic analysis of genomic instability at the 1q12-22 chromosomal site in B-cell non-Hodgkin lymphoma
    Takahiro Itoyama
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Genes Chromosomes Cancer 35:318-28. 2002
    ..Chromosome arm 1q is gene-rich, and characterization of aberrations described in this study can be expected to lead to the discovery of additional functionally significant genetic changes...
  23. ncbi request reprint Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Mod Pathol 18:1350-6. 2005
    ..Additional studies are needed to determine whether epidermal growth factor receptor gene amplification bears any informative value in predicting response to cetuximab-based therapy...
  24. pmc Regulation of B versus T lymphoid lineage fate decision by the proto-oncogene LRF
    Takahiro Maeda
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Science 316:860-6. 2007
    ..We propose a new model for lymphoid lineage commitment, in which LRF acts as a master regulator of the cell's determination of B versus T lineage...
  25. ncbi request reprint Differential expression patterns of c-REL protein in classic and nodular lymphocyte predominant Hodgkin lymphoma
    Qianxun Xiao
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Appl Immunohistochem Mol Morphol 12:211-5. 2004
    ..Our results demonstrate that there is differential c-REL protein expression in cHL in comparison with NLPHL and suggest that c-REL may play a role in the pathogenesis of classic Hodgkin lymphoma...
  26. ncbi request reprint Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial
    Adam D Cohen
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 139:224-33. 2007
    ..Risk-adapted SCT with adjuvant thal/dex is feasible and results in low TRM and high haematological and organ response rates in AL patients...
  27. ncbi request reprint Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease
    Madhav V Dhodapkar
    Laboratory of Tumor Immunology and Immunotherapy, The Rockefeller University, New York, NY 10021, USA
    Cancer Immun 3:9. 2003
    ..These data suggest that CT antigens may have important biological implications in malignant gammopathies and that CT-7 may be a suitable target for T cell-based and possibly antibody-mediated immunotherapy of myeloma...
  28. doi request reprint Insulin-like growth factor-1 receptor expression in thymic malignancies
    Nicolas Girard
    Human Oncology and Pathogenesis Program, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA
    J Thorac Oncol 5:1439-46. 2010
    ..As higher levels of IGF-1R protein expression may be associated with relative sensitivity to anti-IGF-1R antibody treatment, we investigated IGF-1R expression in thymic malignancies...
  29. pmc High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507)
    Yixuan Gong
    Pao Laboratory, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 4:e7273. 2009
    ..The IGF receptor type 1 (IGF-1R) pathway is frequently deregulated in human tumors and has become a target of interest for anti-cancer therapy...
  30. pmc Tumorigenic activity and therapeutic inhibition of Rheb GTPase
    Konstantinos J Mavrakis
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Genes Dev 22:2178-88. 2008
    ..Of these, only eIF4E was able to enhance lymphomagenesis in vivo. In summary, the Rheb GTPase is an oncogenic activity upstream of mTORC1 and eIF4E and a direct therapeutic target of farnesyltransferase inhibitors in cancer...
  31. pmc Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma
    Jonathan H Schatz
    Cancer Biology and Genetics Program, Sloan Kettering Institute for Cancer Research, New York, NY 10065, USA
    J Exp Med 208:1799-807. 2011
    ..Hence, targeting the convergence of oncogenic survival signals on translation initiation is an effective alternative to combinations of kinase inhibitors...
  32. ncbi request reprint The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide
    Owen A O'Connor
    Department of Medicine, Lymphoma, and Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 12:2902-11. 2006
    ..To determine whether the combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen can sensitize human lymphoma to cyclophosphamide...
  33. ncbi request reprint Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma
    Hani Hassoun
    Division of Hematologic Oncology, Department of Medicine, Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 132:155-61. 2006
    ..AD-TD administered with low dose aspirin for deep vein thrombosis prophylaxis was well tolerated and yielded a high response rate with minimal treatment-related morbidity...
  34. pmc Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression
    Li Ma
    Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Genes Dev 19:1779-86. 2005
    ....
  35. ncbi request reprint Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation
    Dorothy Pan
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer J 8:371-6. 2002
    ..In these cases, there is limited salvageability with the use of conventional therapy. The purpose of this retrospective analysis was to evaluate single-agent rituximab as treatment for aggressive non-Hodgkin's lymphomas in these cases...
  36. ncbi request reprint Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts
    Aruna Kode
    Department of Medicine, Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    Nature 506:240-4. 2014
    ....
  37. pmc Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas
    Weiyi Chen
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 107:2477-85. 2006
    ..Overall, array-CGH identified relatively small genomic regions associated with outcome, which, along with follow-up expression studies, may reveal target genes important in DLBCL clinical behavior...
  38. pmc The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma
    Elisa Oricchio
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cell 147:554-64. 2011
    ..Our study attests to the power of combining descriptive tumor genomics with functional screens and reveals EPHA7(TR) as tumor suppressor with immediate therapeutic potential...
  39. pmc Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation
    Ekaterina Doubrovina
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 119:2644-56. 2012
    ....
  40. pmc Ubiquitination regulates PTEN nuclear import and tumor suppression
    Lloyd C Trotman
    Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cell 128:141-56. 2007
    ....
  41. doi request reprint Radiologic features of NUT midline carcinoma in an adolescent
    Daniel G Rosenbaum
    Department of Radiology, New York Presbyterian Hospital Weill Cornell Medical Center, 525 E 68th St, Box 141, New York, NY 10065, USA
    Pediatr Radiol 42:249-52. 2012
    ..A newly described but increasingly recognized disease entity, NMC should enter the differential of pediatric midline tumors displaying particularly aggressive characteristics on imaging...
  42. pmc Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma
    Sarah T Wilkinson
    Department of Pathology, University of Arizona, 1501 N Campbell Avenue, Tucson, AZ 85724 5043, USA
    Blood 119:1459-67. 2012
    ..Our observations provide a possible unifying concept that may contribute to the poor outcome reported in all MHC II(-) B-cell tumors...
  43. pmc Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan
    Ping Zhou
    Sloan Kettering Institute, Department of Pathology, New York, NY 10021, USA
    Blood 111:549-57. 2008
    ....
  44. ncbi request reprint Spectral karyotyping identifies new rearrangements, translocations, and clinical associations in diffuse large B-cell lymphoma
    Gouri Nanjangud
    Cell Biology Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Blood 99:2554-61. 2002
    ..These studies emphasize the value of SKY analysis for redefinition of chromosomal instability in DLBCL to enhance gene discovery as well as clinical correlation analysis...
  45. pmc The role of cytotoxic and regulatory T cells in relapsed/refractory Hodgkin lymphoma
    Aashiyana F Koreishi
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Appl Immunohistochem Mol Morphol 18:206-11. 2010
    ..0001). Expression of cytotoxic and regulatory T-cells shows prognostic significance in the relapsed/refractory clinical setting of cHL...
  46. pmc SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization
    Lydia W S Finley
    Department of Pathology, The Paul F Glenn Labs for the Biological Mechanisms of Aging, Harvard Medical School, Boston, MA 02115, USA
    Cancer Cell 19:416-28. 2011
    ..Finally, we find that SIRT3 overexpression represses glycolysis and proliferation in breast cancer cells, providing a metabolic mechanism for tumor suppression...
  47. ncbi request reprint Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma
    Cyrus V Hedvat
    Laboratory of Cancer Genetics, Cell Biology Program, Department of Pathology and Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Hum Pathol 33:968-74. 2002
    ..This extensive expression profile of B-cell NHLs and HL tissues discloses the ability of TMAs to rapidly screen a large series of cases and represents the first report of method validation for this technique in the study of lymphoma...
  48. ncbi request reprint Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo
    Eunice S Wang
    Laboratory of Developmental Hematopoiesis, Cell Biology Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Blood 104:2893-902. 2004
    ..12, methotrexate) consistently improved tumor responses over those of single-agent therapy. These data support the further clinical development of VEGFR-targeted approaches for the therapy of aggressive DLBCL...
  49. ncbi request reprint Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa
    Rohit Bhargava
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 106:1857-62. 2006
    ..Two antibodies, the PharmDx kit and the 31G7 clone, are used commonly for immunohistochemistry by various laboratories. No comparative studies on the performance of these 2 antibodies are available...
  50. ncbi request reprint Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant
    Jenna D Goldberg
    Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Leuk Lymphoma 53:1124-9. 2012
    ..These data demonstrate that allogeneic transplant is a viable option for the treatment of T-NHL and merits prospective evaluation...
  51. doi request reprint Synchronous follicular lymphoma, kaposi sarcoma, and castleman's disease in a HIV-negative patient with EBV and HHV-8 coinfection
    Aashiyana F Koreishi
    Department of Pathology and Radiology, Memorial Sloan Kettering Cancer Center, New York, USA
    Int J Surg Pathol 19:685-91. 2011
    ....
  52. doi request reprint Expression of Grb2 distinguishes classical Hodgkin lymphomas from primary mediastinal B-cell lymphomas and other diffuse large B-cell lymphomas
    Rodney R Miles
    Department of Pathology, University of Utah, Salt Lake City, UT 84112 0565, USA
    Hum Pathol 40:1731-7. 2009
    ....
  53. pmc Mad2 overexpression promotes aneuploidy and tumorigenesis in mice
    Rocio Sotillo
    Cancer Biology and Genetics Program, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Cell 11:9-23. 2007
    ..These results demonstrate that transient Mad2 overexpression and chromosome instability can be an important stimulus in the initiation and progression of different cancer subtypes...
  54. ncbi request reprint Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma
    Cyrus V Hedvat
    Laboratory of Molecular Aspects of Hematopoiesis, Sloan Kettering Institute, New York, NY, USA
    Br J Haematol 122:728-44. 2003
    ..Defining how malignant plasma cell growth is regulated in the bone marrow versus at extramedullary sites will help to delineate the mechanisms underlying the dependence of tumour cell growth on angiogenesis and cell adhesion...
  55. ncbi request reprint Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy
    Elisa Oricchio
    Cancer Biology and Genetics Program, Computational Biology Program, Department of Medicine, Human Oncology and Pathogenesis Program, Genomics Core Facility, Molecular Pharmacology Program, Department of Pathology, Department of Epidemiology and Biostatistics, and Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065
    J Exp Med 211:1379-91. 2014
    ..We find that dual CDK4 and BCL2 inhibitor treatment is safe and effective against available models of FL. In summary, frequent RB pathway lesions in indolent, high-risk FLs indicate an untapped therapeutic opportunity. ..
  56. ncbi request reprint Posttransplant lymphoproliferative disorder complicating hematopoietic stem cell transplantation in a patient with dyskeratosis congenita
    Olga L Bohn
    1Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Surg Pathol 21:520-5. 2013
    ....
  57. doi request reprint Pancreatic involvement in neuroblastoma with radiologic-pathologic correlation: a single-institution experience
    Daniel G Rosenbaum
    Department of Radiology, New York Presbyterian Hospital and Weill Cornell Medical Center, 525 E 68th St, Box 141, New York, NY 10065, USA
    AJR Am J Roentgenol 201:W141-6. 2013
    ..We present imaging findings of pancreatic involvement in neuroblastoma with clinical and pathologic correlation in the largest documented series to date...
  58. doi request reprint ALK-positive anaplastic large cell lymphoma in a patient with chronic lymphocytic leukemia
    Ting Liu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Int J Surg Pathol 18:424-8. 2010
    ..Despite intensive chemotherapy, the patient died. This case represents the rare occurrence of an ALK-positive ALCL developing in a patient with CLL...
  59. pmc Acetylation-dependent regulation of Skp2 function
    Hiroyuki Inuzuka
    Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Cell 150:179-93. 2012
    ..Thus, our study identifies an acetylation-dependent regulatory mechanism governing Skp2 oncogenic function and provides insight into how cytoplasmic Skp2 controls cellular migration...
  60. ncbi request reprint Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?
    John Gerecitano
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 134:391-8. 2006
    ..In fact, the development of an isolated cutaneous vasculitis may portend a better clinical response to bortezomib in some patients...
  61. ncbi request reprint The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma
    Lorraine E Toner
    Laboratory of Experimental Therapeutics for the Lymphoproliferative Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 12:924-32. 2006
    ....
  62. ncbi request reprint Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma
    Tarun Kewalramani
    Hematology Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 134:202-7. 2006
    ..The outcome of ASCT for patients with chemosensitive relapsed or primary refractory PTCL is similar to that for patients with DLBCL...
  63. pmc LRF is an essential downstream target of GATA1 in erythroid development and regulates BIM-dependent apoptosis
    Takahiro Maeda
    Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Dev Cell 17:527-40. 2009
    ..Thus, our data define a key transcriptional cascade for effective erythropoiesis, whereby GATA-1 suppresses BIM-mediated apoptosis via LRF...
  64. ncbi request reprint Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma
    Eunice S Wang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021 6306, USA
    Cancer 98:1196-205. 2003
    ..In contrast, the safety and efficacy of intensive regimens have not been established for Burkitt lymphoma (BL), a highly aggressive lymphoma for which moderate-dose chemotherapy is substandard in the HIV-negative population...
  65. ncbi request reprint Epstein-Barr virus positive large B-cell lymphoma arising in a patient previously treated with Cladribine for hairy cell leukemia
    Rohit Bhargava
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Leuk Lymphoma 45:1043-8. 2004
    ..Cladribine is a potent immunosuppressive agent and should be included with the list of immunosuppressive agents that may be associated with EBV-related B-cell lymphoproliferative disorders...
  66. ncbi request reprint Immunohistochemical analysis of novel monoclonal antibody PNL2 and comparison with other melanocyte differentiation markers
    Klaus J Busam
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Am J Surg Pathol 29:400-6. 2005
    ..Despite its reactivity with neutrophils, PNL2 appears to be a valuable supplementary reagent for the diagnosis of melanocytic tumors...
  67. ncbi request reprint Primary follicular lymphoma of the testis: excellent outcome following surgical resection without adjuvant chemotherapy
    Kevin N Heller
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York City, New York 10021, USA
    J Pediatr Hematol Oncol 26:104-7. 2004
    ....
  68. ncbi request reprint Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins
    Raymond L Comenzo
    Howard 802, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Blood 107:3489-91. 2006
    ..These results justify further study of screening for hereditary variants in patients with apparent AL, and highlight the need for practical techniques for identifying fibrils extracted from tissue...
  69. doi request reprint ALK-positive diffuse large B-cell lymphoma with the t(2;17)(p23;q23)
    Da Zhang
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Appl Immunohistochem Mol Morphol 17:172-7. 2009
    ..An add(2)(p23) was also seen not previously reported. Differential diagnoses of neoplasms with plasmablastic differentiation and a comprehensive molecular/cytogenetic literature review of ALK+DLBCL is discussed...
  70. ncbi request reprint Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer
    Li Ma
    Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Res 67:7106-12. 2007
    ..Importantly, our results indicate that Erk-mediated phosphorylation and inactivation of TSC2 can be critical in development of hamartomatous lesions in TSC and cancer pathogenesis...
  71. ncbi request reprint Cytologic features of plasmablastic lymphoma
    Oscar Lin
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 105:139-44. 2005
    ..Recent studies have reported this neoplasm also in patients without HIV infection and involving sites other than head and neck. This lymphoma has a heterogeneous morphologic presentation but distinct phenotype...
  72. ncbi request reprint Primary follicular lymphoma of the gastrointestinal tract: a clinical and pathologic study of 26 cases
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, U S A
    Am J Surg Pathol 26:216-24. 2002
    ..The estimated 5-year disease-free survival was 62%, and median disease-free survival was 69 months. The estimated 5-year relapse-free survival was 54%, and the median relapse-free survival was 63 months...
  73. ncbi request reprint Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes
    Guenther Koehne
    Allogeneic Bone Marrow Transplantation Service, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Nat Biotechnol 21:405-13. 2003
    ..This technique for imaging the migration of ex vivo-transduced antigen-specific T cells in vivo is informative, nontoxic, and potentially applicable to humans...
  74. pmc Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB
    Hui Kuan Lin
    Department of Pathology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nat Cell Biol 11:420-32. 2009
    ..Finally, we demonstrate that high levels of activation of Akt correlate with the cytosolic accumulation of Skp2 in human cancer specimens. Our results therefore define a novel proto-oncogenic Akt/PKB-dependent signalling pathway...
  75. doi request reprint Sclerosing angiomatoid nodular transformation (SANT) of the spleen: a report of 3 cases
    Aashiyana F Koreishi
    Department of Pathology, Hospital of the University of Pennsylvania, Philadelphia, USA
    Int J Surg Pathol 17:384-9. 2009
    ..However, in 1 patient, a PET scan revealed positive FDG activity, heightening clinical concern for malignancy...
  76. pmc Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse
    Paolo Sportoletti
    Cancer Biology and Genetics Program, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Blood 111:3859-62. 2008
    ..Our results conclusively demonstrate that Npm1 acts as a haploinsufficient tumor suppressor in the hematopoietic compartment...
  77. doi request reprint Malignant histiocytoses/disseminated histiocytic sarcoma with hemophagocytic syndrome in a patient with mediastinal germ cell tumor
    Hiroko Shinoda
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Appl Immunohistochem Mol Morphol 17:338-44. 2009
    ..Atypical histiocytes stained positive for CD68, CD163, CD4, CD45 (LCA), and S-100. Cytogenetics studies were negative for i12p. The patient was refractory to therapy and ultimately died 5 months after diagnosis...
  78. pmc Role of the chromobox protein CBX7 in lymphomagenesis
    Clare L Scott
    Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA
    Proc Natl Acad Sci U S A 104:5389-94. 2007
    ..These data identify CBX7 as a chromobox protein causally linked to cancer development and may help explain the low frequency of INK4a/ARF mutations observed in human follicular lymphoma...
  79. ncbi request reprint In situ localization of follicular lymphoma: description and analysis by laser capture microdissection
    Peijie Cong
    Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Blood 99:3376-82. 2002
    ..These findings provide insight into the pathophysiology of early FL, and illustrate the utility of immunohistochemistry for early diagnosis...
  80. pmc Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
    Arkaitz Carracedo
    Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, Massachusetts, USA
    J Clin Invest 118:3065-74. 2008
    ....
  81. ncbi request reprint Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants
    Michael T Hemann
    Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, New York 11724, USA
    Nature 436:807-11. 2005
    ....
  82. ncbi request reprint Tumour invasion and metastasis initiated by microRNA-10b in breast cancer
    Li Ma
    Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA
    Nature 449:682-8. 2007
    ....
  83. ncbi request reprint Angioimmunoblastic T-cell lymphoma with an evolving Epstein Barr virus-positive diffuse large B-cell lymphoma with unusual clinical and pathologic findings
    Rodrigo O B Maegawa
    Leuk Lymphoma 48:2071-4. 2007
  84. pmc PML targeting eradicates quiescent leukaemia-initiating cells
    Keisuke Ito
    Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Department of Medicine, Harvard Medical School, New Research Building, 330 Brookline Avenue, Boston, Massachusetts 02215, USA
    Nature 453:1072-8. 2008
    ....
  85. pmc The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network
    Min Sup Song
    Cancer Genetics Program, Beth Israel Deaconess Cancer Center and Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Nature 455:813-7. 2008
    ....